Back to Search Start Over

AstraZeneca, Daiichi Sankyo announce positive results from DESTINY-Breast06 phase III trial of Enhertu

Source :
PharmaBiz. April 30, 2024
Publication Year :
2024

Abstract

Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy [...]

Subjects

Subjects :
AstraZeneca PLC -- Product development
Metastasis -- Analysis
Clinical trials -- Analysis
Pharmaceuticals and cosmetics industries
Enhertu (Medication) -- Product development

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.792080512

Tools

Authors Abstract Subjects Details